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Abstract: Recurrent meningiomas remain a substantial treatment challenge given the lack of effective
therapeutic options aside from surgery and radiation therapy, which yield limited results in the
retreatment situation. Systemic therapies have little effect, and responses are rare; the search for
effective systemic therapeutics remains elusive. In this case report, we provide data regarding
significant responses in two radiographically diagnosed intracranial meningiomas in a patient with
concurrent thyroid carcinoma treated with cabozantinib, an oral multitarget tyrosine kinase inhibitor
with potent activity against MET and VEGF receptor 2. Given the clinical experience supporting the
role of VEGF agents as experimental therapeutics in meningioma and the current understanding of
the biological pathways underlying meningioma growth, this may represent a new oral therapeutic
alternative, warranting prospective evaluation.
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Meningiomas account for approximately one-third of primary central nervous system
tumors in adults. Although most meningiomas are well-differentiated, with low proliferative capacity [1], recent analyses using the updated grading criteria adopted by the World
Health Organization (WHO) have demonstrated that as many as 15% to 20% should be
classified as atypical WHO Grade II [2]. In the Radiation Therapy Oncology Group (RTOG)
0539, a phase II cooperative group trial assessing the safety and efficacy of risk-adapted
meningioma treatment strategies, “high-risk” meningioma patients (WHO grade II subtotal resection, recurrent grade II, or any grade III), experienced a 3-year progression-free
survival (PFS) of only 59%, with a 3-year local control rate of only 69% [3], prompting broad
agreement for the need for more effective multimodality therapy, and the optimization of
treatment strategies in this patient population.
Evaluation of systemic therapies in recurrent and higher grade meningiomas suggest
that most chemotherapeutic agents have minimal to no activity against this disease group.
Agents such as hydroxyurea, dacarbazine, ifosfamide, temozolomide, irinotecan, and αinterferon have demonstrated no clinical efficacy [4]. The pathogenesis of meningioma is
incompletely understood, and studies have now focused on gene expression profiling and
DNA methylation arrays to characterize transcriptional and epigenetic changes in the hope
of identifying prognostic markers and molecular drivers. Emerging data have identified

Curr. Oncol. 2021, 28, 1537–1543. https://doi.org/10.3390/curroncol28020145

https://www.mdpi.com/journal/curroncol

Curr. Oncol. 2021, 28

1538

the upregulation of pathways involved in growth, proliferation, and angiogenesis, including EGFR, mTOR, PDGF, and VEGF, suggesting these as potential actionable targets [5].
Moreover, high MET expression has been demonstrated to be a predictor for recurrence in
meningioma [6].
Markers of angiogenesis, including increased vessel density and VEGF expression, are
detectable in meningiomas, and have been linked with grade and prognosis [7,8]. At least
two VEGF targeting agents have previously been tested in this setting: bevacizumab and
sunitinib. Bevacizumab showed evidence of antitumor activity, including radiographic
responses and prolonged PFS in a retrospective series [9]. A prospective, multi-center
single-arm phase II trial investigated the efficacy of sunitinib, a small molecule tyrosine
kinase inhibitor (TKI), against VEGFR and PDGFR in 36 patients with WHO grade II
and III recurrent or progressive meningiomas, resulting in a very modest median PFS of
5.2 months [10]. Reports focused on recurrent WHO grade I meningiomas are limited.
A phase II study evaluated the combination of bevacizumab and everolimus, an mTOR
inhibitor, in patients with recurrent or progressive meningioma (n = 5 WHO grade I,
17 total) [11]. Interestingly, the median PFS was greater for WHO grade II and III tumors
(22 months) as compared to grade I tumors (17 months). Similarly, another phase II study
investigated the efficacy of Vatalanib, a small molecule protein kinase inhibitor with activity
against VEGF receptors, PDGFR-beta, and c-kit in refractory meningiomas (n = 2 WHO
grade I, 25 total), with overall modest activity [12]. Together, these studies demonstrate the
promise of VEGF inhibitors in meningioma.
Cabozantinib is a multitarget oral TKI with potent activity against MET and VEGF
receptor 2 (VEGFR2) [13]. It is FDA-approved for the treatment of progressive metastatic
medullary thyroid cancer and advanced renal cell carcinoma. In this case study, we report
a patient with metastatic thyroid cancer treated with cabozantinib who demonstrated a
marked response in two previously untreated, incidental intracranial meningiomas. To the
best of our knowledge and based on a search of the medical literature (MEDLINE, accessed
on 29 February 2020), this represents the first documented case of a response to this oral
agent in meningioma and provides an encouraging example for further study.
2. Case Report
A 65-year-old male with a past medical history significant for medically controlled
hypertension presented initially with dysphonia and was found to have a large thyroid
mass displacing the trachea and extending into the superior mediastinum. He underwent a
total thyroidectomy; pathology revealed follicular thyroid carcinoma, insular variant, and
he was treated with 200 mCi of oral radioactive iodine (RAI). A seven-day post-iodine scan
revealed evidence of significant residual iodine-avid tissue within the thyroid bed, as well
as multiple non-calcified pulmonary nodules with increased iodine uptake suspicious for
bilateral metastatic pulmonary disease. He later developed symptomatic local recurrence,
as well as an increase in the burden of distant metastatic disease, approximately 1 year
after resection, and 9 months after RAI. He was treated with Lenvatinib 20 mg PO once
daily. After a few weeks, he continued to have persistent symptoms of vocal cord paralysis
and, given concern for persistent disease, underwent total laryngopharyngectomy, cervical
esophagectomy, and post-operative external beam radiotherapy, and his systemic therapy
was discontinued. MRIs of the spine at that time revealed a T12 metastasis with an epidural
tumor treated with stereotactic body radiotherapy.
At age 70, five years after initial presentation, he presented with headaches, and
an MRI scan of the brain revealed a left posterior frontal parafalcine lesion measuring
2 × 1.5 × 2.5 cm, along with two stable intraventricular meningiomas (measuring approximately 8.5 and 9.2 mm each). Interval brain MRI performed 2.5 months later, at the time
of transfer to our center, revealed that the left parafalcine mass had increased in size to
3.5 × 3.4 × 2.4 cm, with moderate mass effect on the motor strip, with the two intraventricular putative meningiomas stable in size. Given the patient’s progressive weakness
and lesion size, he underwent resection of the left posterior frontal parafalcine mass, and
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Table 1. Selected clinical studies evaluating the use of VEGF agents in meningioma patients.
Author and
Year

Studied
Drug

Mechanism of
Action

Study Type

Number of
Patients

Prior
Surgery

Prior RT *

WHO Grade
Inclusion

PFS 6 **

Puchner et al.,
2010 [14]

Bevacizumab

Anti-VEGF
antibody

Case report

1

1

1

III

NA

Goutagny
et al., 2011 [15]

Bevacizumab

Anti-VEGF
antibody

Case report

1

NA

NA

NA

NA

Lou et al.,
2012 [16]

Bevacizumab

Anti-VEGF
antibody

Retrospective

14

14

11

I,II,III

86%

Nayak et al.,
2012 [17]

Bevacizumab

Anti-VEGF
antibody

Retrospective

15

15

15

II,III

44%

Nunes et al.,
2013 [18]

Bevacizumab

Anti-VEGF
antibody

Retrospective

15

NA

NA

NA

93%

Hawasli et al.,
2013 [19]

Bevacizumab,
Pazopanib

Anti-VEGF
antibody, TKI

Retrospective

10

9

5

NA

NA

Raizer et al.,
2014 [12]

Vatalanib

VEGFR +
PDGFR TKI

Phase II

17

16

12

I,II,III

60%

Alanin et al.,
2015 [20]

Bevacizumab

Anti-VEGF
antibody

Retrospective

7

NA

NA

NA

NA

Kaley et al.,
2015 [10]

Sunitinib

VEGFR +
PDGFR TKI

Phase II

36

36

35

II,III

42%

Furtner et al.,
2015 [21]

Bevacizumab

Anti-VEGF
antibody

Retrospective

5

NA

NA

II,III

NA

Grimm et al.,
2015 [22]

Bevacizumab

Anti-VEGF
antibody

Phase II

40

40

40

I,II,III

27%

Shih et al., 2016
[11]

Bevacizumab,
Everolimus

Anti-VEGF
antibody

Phase II

17

16

12

I,II,III

69%

* RT = radiotherapy; ** 6-month progression-free survival.

Sunitinib demonstrated promising activity in a phase II meningioma trial [10]; however, in untreated renal cell carcinoma brain metastasis, the objective response rate was
0% [23]. There are currently only three ongoing phase II prospective trials for patients
with sporadic recurrent or progressive meningioma: one using bevacizumab monotherapy
(NCT01125046), another studying a combination of bevacizumab and electric field therapy (NCT02847559), and a third evaluating the activity of a single agent PD-1 inhibitor
Pembrolizumab (NCT03279692) (see Supplemental Table S1).
Cabozantinib is a small molecule inhibitor of multiple tyrosine kinases including MET,
VEGFR2, RET, and AXL. Selective inhibition of VEGFR2 may lead to increased invasiveness
and metastasis, and preclinical models suggest that the inhibition of VEGFR2, together with
c-MET, may decrease tumor size and invasiveness [24]. Cabozantinib was FDA approved in
2012 for patients with progressive metastatic medullary thyroid cancer based on improved
PFS compared to placebo (11.2 months vs. 4.0 months, p < 0.001) [25]. In 2016, cabozantinib
was approved for adults with advanced renal cell carcinoma following prior antiangiogenic
therapy and, subsequently, in the first-line setting [26]. There has also been documented
experience of treatment of primary intracranial tumors with cabozantinib. A phase II
trial examined the efficacy and safety of cabozantinib in 222 patients with progressive or
recurrent GBM, and initial results demonstrated modest clinical activity in patients who
had received prior antiangiogenic therapy [27]. More promising activity was observed in a
subsequent subset of 152 patients not previously treated with antiangiogenic therapy (ORR
of 15% for the combined dosing cohorts and a median PFS of 3.7 months in both cohorts)
(see Supplemental Table S2) [28]. Therefore, this agent likely has intracranial penetration
(not a requirement for meningioma) based on the limited efficacy in recurrent GBM.
Several limitations are to be noted from this case example. First, the lack of histopathological evaluation of the intraventricular lesions prevents a definitive diagnosis from being
made and precludes biomarker evaluation. However, this was not clinically indicated in
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this patient, as the intraventricular lesions were present and stable during the patient’s
cancer course and responded to the systemic therapy (unexpectedly); therefore, pathological evaluation has not been necessary. We do consider these lesions to be meningiomas
versus brain metastasis for the following reasons: (1) the development of the single brain
metastasis and its progression in size while treatment was arranged in the setting of the
intraventricular lesions remaining stable during interval imaging; (2) the rarity of intraventricular brain metastases, representing only 1–5% of cases in general [29] and only a
single case report of an intraventricular thyroid cancer metastasis reported in the literature [30]; (3) radiographic and biopsy-proven extracranial disease progression now over
1 year from the initiation of cabozantinib, along with intracranial disease progression with
development of additional intracranial lesions, but continued response and stability of the
intraventricular lesions, which would be strikingly discordant. An additional limitation to
note is that this particular patient was presumed to have low-grade meningiomas based
on their lack of growth trajectory and imaging appearance and responded to single agent
Cabozantinib. Therefore, although similar VEGFR-directed agents have been utilized in
those with higher grade recurrent or progressive disease, the responses may differ across
different grades of meningioma, and the evaluation of the molecular underpinnings are
key to better understanding the response assessments.
Additionally, the development of non-invasive or liquid biomarkers are equally important, especially if pathological evaluation is unable to be performed, such as in this
particular case. Recently, non-invasive techniques, such as liquid biopsy or CSF analysis,
have emerged as viable options in this space [31,32]. Circulating microRNAs (miRNAs)
and DNA methylation hold great promise as novel clinical blood-based biomarkers for
meningioma diagnosis and prognosis [33,34]. Currently, many more biomarkers are being
identified, and research on the effectiveness of these techniques is being performed to
determine their usefulness for the detection and monitoring of genomic alterations [31].
Additionally, we also considered, in this case, whether the radiographic response was
primarily due to vasculature changes as a result of the targeted therapy or a direct effect on
the meningioma cells, as it is known that meningiomas do not show an angiogenic switch
involving VEGF, as is the case with gliomas. Nevertheless, the biological activity of VEGF
and the molecular underpinnings behind meningioma proliferation suggest that it is a
potential target for antiangiogenic therapy in meningiomas of all WHO grades.
4. Conclusions
Meningiomas are common tumors in a neuro-oncology practice, but there are few systemic options for patients with recurrent disease. Clinical experience with VEGF inhibitors
demonstrates modest results. This case of a patient treated with the oral agent cabozantinib,
with potent activity against MET and VEGFR2, may represent a new therapeutic option
in this patient population with a highly unmet need. Unfortunately, we did not have
actual tumor tissue from any of the lesions, as resection was not clinically indicated and
therefore correlating the response with biomarker expression is not possible. Moreover,
these lesions were stable over multiple MRIs, and radiographically most consistent with
meningioma, unlike the known and resected thyroid metastatic lesion in the brain. Given
the preclinical understanding of the molecular underpinnings of meningioma and the
lack of effective systemic therapeutic options, a prospective evaluation of Cabozantinib
is encouraged and warranted in patients with relapsed or refractory disease. This study
is currently in development with the objectives of evaluating the PFS, overall response
rate, overall survival, safety and tolerability, and quality of life for patients treated for
recurrent meningioma of WHO Grades I–III. Correlation of MET expression, angiogenesis
receptor status, and inflammatory signatures by gene expression profiling with response
to cabozantinib on pre-treatment tissue samples will lead to a better understanding of
this potential therapeutic modality. Similar initiatives are encouraged in this space to help
provide alternatives for this challenging disease.
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